291 related articles for article (PubMed ID: 24970389)
1. Boolean ErbB network reconstructions and perturbation simulations reveal individual drug response in different breast cancer cell lines.
von der Heyde S; Bender C; Henjes F; Sonntag J; Korf U; Beißbarth T
BMC Syst Biol; 2014 Jun; 8():75. PubMed ID: 24970389
[TBL] [Abstract][Full Text] [Related]
2. Chronic morphine treatment attenuates cell growth of human BT474 breast cancer cells by rearrangement of the ErbB signalling network.
Weingaertner IR; Koutnik S; Ammer H
PLoS One; 2013; 8(1):e53510. PubMed ID: 23308242
[TBL] [Abstract][Full Text] [Related]
3. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
[TBL] [Abstract][Full Text] [Related]
4. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.
Diermeier-Daucher S; Breindl S; Buchholz S; Ortmann O; Brockhoff G
Cytometry A; 2011 Sep; 79(9):684-93. PubMed ID: 21786419
[TBL] [Abstract][Full Text] [Related]
5. Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach.
Lange F; Rateitschak K; Kossow C; Wolkenhauer O; Jaster R
World J Gastroenterol; 2012 Nov; 18(43):6226-34. PubMed ID: 23180942
[TBL] [Abstract][Full Text] [Related]
6. MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer.
Qi W; Cooke LS; Stejskal A; Riley C; Croce KD; Saldanha JW; Bearss D; Mahadevan D
BMC Cancer; 2009 May; 9():142. PubMed ID: 19432987
[TBL] [Abstract][Full Text] [Related]
7. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.
O'Brien NA; Browne BC; Chow L; Wang Y; Ginther C; Arboleda J; Duffy MJ; Crown J; O'Donovan N; Slamon DJ
Mol Cancer Ther; 2010 Jun; 9(6):1489-502. PubMed ID: 20501798
[TBL] [Abstract][Full Text] [Related]
8. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
[TBL] [Abstract][Full Text] [Related]
9. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
Yao E; Zhou W; Lee-Hoeflich ST; Truong T; Haverty PM; Eastham-Anderson J; Lewin-Koh N; Gunter B; Belvin M; Murray LJ; Friedman LS; Sliwkowski MX; Hoeflich KP
Clin Cancer Res; 2009 Jun; 15(12):4147-56. PubMed ID: 19509167
[TBL] [Abstract][Full Text] [Related]
10. Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines.
Holland WS; Chinn DC; Lara PN; Gandara DR; Mack PC
J Cancer Res Clin Oncol; 2015 Apr; 141(4):615-26. PubMed ID: 25323938
[TBL] [Abstract][Full Text] [Related]
11. Early changes in [18F]FDG incorporation by breast cancer cells treated with trastuzumab in normoxic conditions: role of the Akt-pathway, glucose transport and HIF-1α.
Fleming IN; Andriu A; Smith TA
Breast Cancer Res Treat; 2014 Apr; 144(2):241-8. PubMed ID: 24522376
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
[TBL] [Abstract][Full Text] [Related]
13. The receptor tyrosine kinase inhibitor vandetanib activates Akt and increases side population in a salivary gland tumor cell line (A253).
Fujishiro Y; Tonogi M; Ochiai H; Matsuzaka K; Yamane GY; Azuma T
Int J Oncol; 2012 Jul; 41(1):362-8. PubMed ID: 22576692
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells.
Bezler M; Hengstler JG; Ullrich A
Mol Oncol; 2012 Oct; 6(5):516-29. PubMed ID: 22841590
[TBL] [Abstract][Full Text] [Related]
15. Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.
D'Alessio A; De Luca A; Maiello MR; Lamura L; Rachiglio AM; Napolitano M; Gallo M; Normanno N
Breast Cancer Res Treat; 2010 Sep; 123(2):387-96. PubMed ID: 19946741
[TBL] [Abstract][Full Text] [Related]
16. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.
Normanno N; Campiglio M; De LA; Somenzi G; Maiello M; Ciardiello F; Gianni L; Salomon DS; Menard S
Ann Oncol; 2002 Jan; 13(1):65-72. PubMed ID: 11863114
[TBL] [Abstract][Full Text] [Related]
17. Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition.
Goltsov A; Faratian D; Langdon SP; Mullen P; Harrison DJ; Bown J
Cell Signal; 2012 Feb; 24(2):493-504. PubMed ID: 21996585
[TBL] [Abstract][Full Text] [Related]
18. Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance.
Sahin O; Fröhlich H; Löbke C; Korf U; Burmester S; Majety M; Mattern J; Schupp I; Chaouiya C; Thieffry D; Poustka A; Wiemann S; Beissbarth T; Arlt D
BMC Syst Biol; 2009 Jan; 3():1. PubMed ID: 19118495
[TBL] [Abstract][Full Text] [Related]
19. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.
O'Brien NA; McDonald K; Tong L; von Euw E; Kalous O; Conklin D; Hurvitz SA; di Tomaso E; Schnell C; Linnartz R; Finn RS; Hirawat S; Slamon DJ
Clin Cancer Res; 2014 Jul; 20(13):3507-20. PubMed ID: 24879796
[TBL] [Abstract][Full Text] [Related]
20. Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models.
Crafter C; Vincent JP; Tang E; Dudley P; James NH; Klinowska T; Davies BR
Int J Oncol; 2015 Aug; 47(2):446-54. PubMed ID: 26095475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
